

Attorney Docket No. PU498 Sw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE: Application of Sarah S. BACUS et al.

Serial No.: 10/529,922

Art Unit: To be Assigned

Filing Date: March 30, 2005

Examiner: To be Assigned

For: Predictive Markers in Cancer Therapy

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed
- ☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_ (37 CFR 1.98(d))
- ☐ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:  
(1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311,  
whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: 7/27/05


Patty Wilson  
Patty Wilson

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

  
\_\_\_\_\_  
Virginia G. Campen  
Attorney of Record  
Registration No. 37,092

Date: 26 July 05  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1012  
Facsimile: (919) 483-7988

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>SERIAL NO.</b>		10/529,922	
				<b>FILING DATE</b>		March 30, 2005	
				<b>APPLICANT</b>		BACUS et al.	
				<b>GROUP</b>			
				<b>EXAMINER</b>			
				<b>ATTORNEY DOCKET NO.</b>		PU4995USw	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>		<b>Patent Number</b>	<b>Issue Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
	1.	6,001,580	12/14/1999	Tani et al.			
Continue on page _____							
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>Document Number</b>	<b>Publication Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation Yes   No</b>
Continue on page _____							
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
	2.	ALBANELL et al., Pharmacodynamic Studies with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839, <i>Seminars in Oncology</i> <b>28(5)</b> , Suppl 16:56-66 (2001).					
	3.	ALBANELL et al., Activated Extracellular Signal-regulated Kinases: Association with Epidermal Growth Factor Receptor/Transforming Growth Factor $\alpha$ Expression in Head and Neck Squamous Carcinoma and Inhibition by Anti-Epidermal Growth Factor Receptor Treatments, <i>Cancer Research</i> <b>61</b> :6500-6510 (2001).					
	4.	ANDERSON et al., ZD1839 (IRESSA), A Novel Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Potently Inhibits the Growth of EGFR-Positive Cancer Cell Lines With or Without ERBB2 Overexpression, <i>Int. J. Cancer</i> <b>94</b> :774-782 (2001).					
	5.	FILARDO et al., Estrogen-Induced Activation of Erk-1 and Erk-2 Requires the G Protein-Coupled Receptor Homolog, GPR30, and Occurs via Trans-Activation of the Epidermal Growth Factor Receptor through Release of HB-EGF, <i>Molecular Endocrinology</i> <b>14(10)</b> :1649-1660 (2000).					
	6.	GEE et al., Phosphorylation of Erk1/2 Mitogen-Activated Protein Kinase is Associated with Poor Response to Anti-Hormonal Therapy and Decreased Patient Survival in Clinical Breast Cancer, <i>Int. J. Cancer</i> <b>95</b> :247-254 (2001).					
	7.	PAWELETZ et al., Reverse Phase Protein Microarrays which Capture Disease Progression Show Activation of Pro-survival Pathways at the Cancer Invasion Front, <i>Oncogene</i> <b>20</b> :1981-1989 (2001).					
	8.	RUSNAK et al., The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in <i>Vitro</i> and in <i>Vivo</i> , <i>Molecular Cancer Therapeutics</i> <b>1</b> :85-94 (2001).					
	9.	SOLORZANO et al., In <i>Vivo</i> Intracellular Signaling as a Marker of Antiangiogenic Activity, <i>Cancer Research</i> <b>61</b> :7048-7051 (2001).					
Continue on page _____							
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>		
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							